{"name":"Puma Biotechnology, Inc.","slug":"puma","ticker":"PBYI","exchange":"NASDAQ","domain":"pumabiotechnology.com","description":"Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., ","hq":"Los Angeles, CA","founded":2010,"employees":"179","ceo":"Alan H. Auerbach","sector":"Specialty Oncology","stockPrice":7.2,"stockChange":0.03,"stockChangePercent":0.42,"marketCap":"$366M","metrics":{"revenue":227178000,"revenueGrowth":-2.6,"grossMargin":74.5,"rdSpend":0,"netIncome":24384000,"cash":101545000,"dividendYield":0,"peRatio":15,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Nerlynx patent cliff ($0.0B at risk)","drug":"Nerlynx","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HKI-272","genericName":"HKI-272","slug":"hki-272","indication":"Metastatic breast cancer, HER2 positive","status":"phase_2"}]}],"pipeline":[{"name":"HKI-272","genericName":"HKI-272","slug":"hki-272","phase":"phase_2","mechanism":"HKI-272 is a small molecule inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase.","indications":["Metastatic breast cancer, HER2 positive","Locally advanced or metastatic breast cancer, HER2 positive"],"catalyst":""}],"recentEvents":[{"date":"2022-06-30","type":"earnings","headline":"Puma Biotechnology Reports Second Quarter 2022 Financial Results","summary":"Puma Biotechnology reported its second quarter 2022 financial results, with net sales of $43.8 million.","drugName":"","sentiment":"neutral"},{"date":"2022-03-01","type":"deal","headline":"Puma Biotechnology Announces Collaboration with Pfizer to Develop and Commercialize Nerlynx in China","summary":"Puma Biotechnology announced a collaboration with Pfizer to develop and commercialize Nerlynx in China.","drugName":"","sentiment":"positive"},{"date":"2021-06-25","type":"regulatory","headline":"FDA Approves Nerlynx for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer","summary":"The FDA approved Nerlynx for the extended adjuvant treatment of early stage HER2-positive breast cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQnJCRmx0OEFHOVVRVG55Z1pPeHIwVGcxdWhSNnVsUkhpem1xUnU4ZlFySnEzbmhJZ1RZR0pwWUhndTRMNjMxSjVNLVdYNUg2WXdBYUplOFo5cUlvT2p5aXJDaGZ4bVJ5NGplS0hSYU5yVEY1RU9jTzFVR1N4bU4wMllhaEdOWXU3U0dMLXNYckRVS19qRmhfQzJVWlB6NkNOcll4VjVBWFVEMFhKaDJFYnhndFN1SldPczJjOVVON1Y?oc=5","date":"2026-03-18","type":"pipeline","source":"TradingView","summary":"Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - TradingView","headline":"Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOTW1kaVowOU1VS24xNFlfMXhWSktQaDdIb0ZaUDFJQTk4aGtXUGlHUkNkcGo4SDJCd01JWlc0X0hJSVBZcHpPeGJoLW5JN190WkQ2NDY4SVpwVjJOYlVPQVZrVVFYVFh3RXhfSENTVlNtdk03MzBPWTYzVVNaVl8tRVpva2RkNlRJVzJremFtRGRUNGQ0TVlTZ2NCZ2ZIVWkwX3JZNWlGQzY4Q0tYeElmUlRySjhyeDhqLWc?oc=5","date":"2026-02-27","type":"earnings","source":"BioSpace","summary":"Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace","headline":"Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPSXprbHB2U1JPZl9nZGFNams4Vk92YTlVRjg5SkQwNm01Y29ZQVcwM2ZRUDZZbjhKZmZ2RXlHZUNwLWVaZWRQb2FMZV9oTnBnUWpUOC1yNkJ0ZXdtWC1lOTVadTRtOFNUX1NnckxrRUdod1o4VGR6S09BaEtQWDhqS2wyQ0RadU0?oc=5","date":"2026-02-24","type":"earnings","source":"Yahoo Finance","summary":"Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance","headline":"Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5DV25aYXN0aURCLUNSNXRfeVFFNWJxZmU4QjZxWTk4RjZiNHZWOWNNNmdmamV4eXhEQ1RDMlM0LVFzbjEySWdEdUZiMmZzTDBfYm9lZHBQd1dtLXZSODlIX2tIUDlDcmVGd3FNaDBkVU5kVjZ3d2dv?oc=5","date":"2025-11-27","type":"pipeline","source":"Yahoo Finance","summary":"IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? - Yahoo Finance","headline":"IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNUFZKZUZPLVFwb3RLQlFrWDIzMkdUYTlhSmQ4b1NuY1FFdHYya0NOY3doREd5ODN0cTFoejg4aUVMOUhyakZlcDF5Tk1TQ01lOGppNU1zNngwTWpoa1NSUmpyUUREUlo4a25SdnNxWDN6NThpMFlwLU5pVHVkYVZYdnBydUdGTGdKWk5ua1V1QjI4STNJYjN4RGc1SQ?oc=5","date":"2025-11-10","type":"pipeline","source":"Seeking Alpha","summary":"Puma Biotechnology: Step By Step In Making A Transition (NASDAQ:PBYI) - Seeking Alpha","headline":"Puma Biotechnology: Step By Step In Making A Transition (NASDAQ:PBYI)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-07","type":"pipeline","source":"simplywall.st","summary":"Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st","headline":"Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-11","type":"pipeline","source":"simplywall.st","summary":"Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet? - simplywall.st","headline":"Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOVnpoRnMybkpMUXdCSWJ3ZWRXeklodURoMDhmZnhwWmVocW1tZDB2WGtiU2RYbHBWV0xhWnNwejJXSHFEN1dBNXVFVEhJLXM3Skl2SG1LbXdXc2hBNTB5ZFFKcWJCbXQtNnlrXzdQSExaUGVPSFNJTTJoaWhaaFNZVEU5X3RFNkY3end2UUo3QkFGLWJ2cWhuSy1KZ1c2MURLZEJxbmkwMXJaZl9WYzc0ekt5Zw?oc=5","date":"2025-05-09","type":"pipeline","source":"Investing.com","summary":"Puma Biotech CCO Jeff Ludwig departs, no replacement named - Investing.com","headline":"Puma Biotech CCO Jeff Ludwig departs, no replacement named","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNZUZ6ZkR0X2lwVWI1c1oyLW55eEdzNUJWNlF2VjZzU2ptZ3BEV0VObmdSWDNpa2RFZ1lYN2t1Zm5yZE1Mb3FNdHM0N1dNOHFzZXlQTzN6UXZodzFZSWR1MFlJeFNjOTFKQWtOM3pxcF9VVGdBV0Z0bVJxTzZiaGExWUJvLUk?oc=5","date":"2024-05-24","type":"pipeline","source":"Yahoo Finance","summary":"Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why - Yahoo Finance","headline":"Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBYeTVQcTR3U0xtN2E5a2s2eW9FV3B1LUhsY2VnZl9ZSjVIcFRsVE4xRWpfMGIybkIyVXFDM2dkY0VtLWNKMXN4d2xUNlBERTdj?oc=5","date":"2024-04-09","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPakRJSlpmNXhtZEFJa0V3OXFYQmZaT2V6Zmo4VlBqeXc4Z3BCcHBqOTUzWnIyNXBCY19HYzlzTTVkOUxvOTRWZ2FqU19QMEtNcHpyR1hNWG85MEt2dTdGdkhhdUdjanA4aWliaUZJdG00aUE5QlgweVpzTnc5Mm8tZnlWZFNpRjdGaTF2MHl2WkVTQ0lMVkROWVBhdzk5UQ?oc=5","date":"2019-05-10","type":"pipeline","source":"The Motley Fool","summary":"Here's Why Puma Biotechnology Fell as Much as 40.7% Today - The Motley Fool","headline":"Here's Why Puma Biotechnology Fell as Much as 40.7% Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9kWXRBTkczOW5vVVRNRFZzdzZuLU5fdExOLUhuWEhwYXpXTzBGYmt4WXZINmV0WkQzWXYxMTMtS1NFMExwTm5rVGgxYjlVRUN3WDNPeWFpOEw4MVhk?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"PBYI Stock Price and Chart — NASDAQ:PBYI - TradingView","headline":"PBYI Stock Price and Chart — NASDAQ:PBYI","sentiment":"neutral"}],"patents":[{"drugName":"Nerlynx","drugSlug":"neratinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Genentech","Roche","Pfizer"],"therapeuticFocus":["Oncology","Breast Cancer"],"financials":{"source":"yahoo_finance","revenue":228371000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":228371000},{"period":"2024-12-31","value":230468000},{"period":"2023-12-31","value":235637000},{"period":"2022-12-31","value":228031000}],"grossProfit":170214000,"grossProfitHistory":[{"period":"2025-12-31","value":170214000},{"period":"2024-12-31","value":166064000},{"period":"2023-12-31","value":172955000},{"period":"2022-12-31","value":172938000}],"rdSpend":62068000,"rdSpendHistory":[{"period":"2025-12-31","value":62068000},{"period":"2024-12-31","value":54935000},{"period":"2023-12-31","value":50382000},{"period":"2022-12-31","value":52240000}],"sgaSpend":71209000,"operatingIncome":37299000,"operatingIncomeHistory":[{"period":"2025-12-31","value":37299000},{"period":"2024-12-31","value":30966000},{"period":"2023-12-31","value":32640000},{"period":"2022-12-31","value":30720000}],"netIncome":31111000,"netIncomeHistory":[{"period":"2025-12-31","value":31111000},{"period":"2024-12-31","value":30278000},{"period":"2023-12-31","value":21591000},{"period":"2022-12-31","value":2000}],"eps":0.61,"epsHistory":[{"period":"2025-12-31","value":0.61},{"period":"2024-12-31","value":0.62},{"period":"2023-12-31","value":0.45},{"period":"2022-12-31","value":0}],"cash":29635000,"cashHistory":[{"period":"2025-12-31","value":29635000},{"period":"2024-12-31","value":69219000},{"period":"2023-12-31","value":84585000},{"period":"2022-12-31","value":76201000}],"totalAssets":216302000,"totalLiabilities":85962000,"totalDebt":28546000,"equity":130340000,"operatingCashflow":41802000,"operatingCashflowHistory":[{"period":"2025-12-31","value":41802000},{"period":"2024-12-31","value":38918000},{"period":"2023-12-31","value":27009000},{"period":"2022-12-31","value":-15827000}],"capex":-71000,"capexHistory":[{"period":"2025-12-31","value":-71000},{"period":"2024-12-31","value":-56000},{"period":"2023-12-31","value":-12640000},{"period":"2022-12-31","value":-7000000}],"freeCashflow":41731000,"dividendsPaid":null,"buybacks":null,"employees":179,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":18379000,"ebit":18226000,"ebitda":20883000,"period":"2025-12-31","revenue":75453000,"epsBasic":0.27,"netIncome":13438000,"rdExpense":16841000,"epsDiluted":0.26,"grossProfit":52326000,"operatingIncome":17106000},{"sga":17030000,"ebit":10732000,"ebitda":13454000,"period":"2025-09-30","revenue":54475000,"epsBasic":0.18,"netIncome":8844000,"rdExpense":15912000,"epsDiluted":0.17,"grossProfit":42302000,"operatingIncome":9573000},{"sga":18409000,"ebit":8002000,"ebitda":10765000,"period":"2025-06-30","revenue":52436000,"epsBasic":0.12,"netIncome":5855000,"rdExpense":15452000,"epsDiluted":0.12,"grossProfit":40135000,"operatingIncome":6636000},{"sga":17391000,"ebit":5444000,"ebitda":8240000,"period":"2025-03-31","revenue":46007000,"epsBasic":0.06,"netIncome":2974000,"rdExpense":13863000,"epsDiluted":0.06,"grossProfit":35451000,"operatingIncome":3984000},{"sga":17020000,"ebit":14859000,"ebitda":17700000,"period":"2024-12-31","revenue":59077000,"epsBasic":0.39,"netIncome":19305000,"rdExpense":15169000,"epsDiluted":0.39,"grossProfit":45156000,"operatingIncome":13365000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":7.2,"previousClose":7.17,"fiftyTwoWeekHigh":7.9,"fiftyTwoWeekLow":2.85,"fiftyTwoWeekRange":"2.85 - 7.9","fiftyDayAverage":6.88,"twoHundredDayAverage":5.8,"beta":1.23,"enterpriseValue":279358112,"forwardPE":20.6,"priceToBook":2.78,"priceToSales":1.61,"enterpriseToRevenue":1.23,"enterpriseToEbitda":7.09,"pegRatio":0,"ebitda":39413000,"ebitdaMargin":17.3,"freeCashflow":44085376,"operatingCashflow":53606000,"totalDebt":15954000,"debtToEquity":12.4,"currentRatio":2.38,"returnOnAssets":9.5,"returnOnEquity":21.6,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":1,"targetMeanPrice":5,"targetHighPrice":5,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":15.4,"institutionHeldPercent":75.3,"sharesOutstanding":50899456,"floatShares":39092309,"sharesShort":4105615,"shortRatio":15.23,"shortPercentOfFloat":8.1,"epsTrailing":0.48,"epsForward":0.35,"revenuePerShare":4.51,"bookValue":2.59,"officers":[{"age":55,"name":"Mr. Alan H. Auerbach","title":"Founder, Chairman, President, CEO & Secretary"},{"age":56,"name":"Mr. Maximo F. Nougues","title":"CFO & Principal Accounting Officer"},{"age":60,"name":"Mr. Douglas  Hunt B.Sc., FRAPS","title":"Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer"},{"age":null,"name":"Mr. Mariann  Ohanesian","title":"Senior Director of Investor Relations"},{"age":null,"name":"Ms. Heather  Blaber","title":"Senior Vice President of Marketing"},{"age":null,"name":"Mr. Roger L. Storms","title":"Senior Vice President of Sales"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.pumabiotechnology.com","phone":"424 248 6500"}}